DLP-114 – Risperidone 6-12 month Formulation
Delpor’s DLP-114 is a 6-12 month formulation of Risperidone. The product is using Delpor’s ProzorTM technology and the medication is released from Delpor’s subcutaneous implant device. The system enables zero order release kinetics and it is expected to maintain therapeutic levels of Risperidone and its active metabolite in human plasma for at least 6 months and potentially as long as one year.
DLP-119 – Olanzapine 3 month Formulation
DLP-119 is a 3 month formulation of Olanzapine. The product is using Delpor’s ProzorTMtechnology and the medication is released from Delpor’s subcutaneous implant device. The system enables zero order release kinetics and it is expected to maintain therapeutic levels of the drug during a period of 3 months after implantation.
DLP-202 – hGH 3 month Formulation
DLP-202 is a system capable of delivering therapeutic levels of human growth hormone for 3 months. The product is using Delpor’s NANOPORTM technology enabling the sustained zero order release of the medication through constrained diffusion. The medication is released from Delpor’s subcutaneous implant device.
DLP-414 – Exenatide 3-6 month Formulation
DLP-414 is a system capable of delivering therapeutic levels of exenatide for 3-6 months. The product is using Delpor’s NANOPORTM technology enabling the sustained zero order release of the medication through constrained diffusion. The NANOPORTM technology has already been validated, and shown to release several proteins and peptides with near zero-order kinetics in vitro and in vivo. The medication is released from Delpor’s subcutaneous implant device. The prototype device is 4cm and length and 4 mm in diameter but given the high potency of exenatide it could be made smaller.
